| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 4 analysts have evaluated Aflac (NYSE:AFL), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 0 | 2 | 1 | 1 |
| Last 30D | 0 | 0 | 0 | 0 | 1 |
| 1M Ago | 0 | 0 | 0 | 1 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts have recently evaluated Aflac and provided 12-month price targets. The average target is $78.25, accompanied by a high estimate of $80.00 and a low estimate of $75.00. This current average reflects an increase of 9.44% from the previous average price target of $71.50.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Aflac. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Alex Scott | Goldman Sachs | Raises | Sell | $75.00 | $61.00 |
| Thomas Gallagher | Evercore ISI Group | Raises | Underperform | $78.00 | $76.00 |
| Nigel Dally | Morgan Stanley | Raises | Equal-Weight | $80.00 | $75.00 |
| Jimmy Bhullar | JP Morgan | Raises | Neutral | $80.00 | $74.00 |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Aflac's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Aflac analyst ratings.
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Aflac's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 5.69%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Aflac's net margin excels beyond industry benchmarks, reaching 31.51%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Aflac's ROE excels beyond industry benchmarks, reaching 7.28%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Aflac's ROA stands out, surpassing industry averages. With an impressive ROA of 1.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.31.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AFL
